Answers are grounded in this paper and cite their sources.
CC-486 maintenance therapy was associated with significantly longer overall and relapse-free survival than placebo among older patients with AML who were in remission after chemotherapy. Side effects were mainly gastrointestinal symptoms and neutropenia. Quality-of-life measures were maintained throughout treatment. (Supported by Celgene; QUAZAR AML-001 ClinicalTrials.gov number, NCT01757535.).
No takes yet. Share an insight, caveat, or question.
Wei et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: